TABLE 1.
Models | Age | Description | Phenotype |
MSTN KO | 8 weeks | FVB mice harboring a constitutive deletion of the third MSTN exon | Hypertrophy |
mTrFS | 6 weeks | C57Bl/6 transgenic mice overexpressing the human FS 288 specifically in skeletal muscle | Hypertrophy |
pM1-hFS288 | 14 weeks | Plasmid coding for the human FS 288 fused to the c-myc tag was transfected into TA muscle of C57Bl/6 mice which were euthanized 17 days later | Hypertrophy |
sActRIIB 1x | 8 weeks | C57Bl/6 mice treated with 1 injection of 10 mg/kg sActRIIB or PBS and euthanized 48 h after the injection | Hypertrophy |
sActRIIB 2x | 8–9 weeks | C57Bl/6 mice treated with 2 injections of 10 mg/kg sActRIIB or PBS, with injections being 48 h apart, and euthanized 48 h after the last injection | Hypertrophy |
sActRIIB 4x | 8–9 weeks | C57Bl/6 mice treated with 4 injections of 10 mg/kg sActRIIB or PBS, with injections being 48 to 72 h apart, and euthanized 48 h after the last injection | Hypertrophy |
pcDNA-MSTN | 8 weeks | Plasmid coding for the murine MSTN transfected into TA muscle of FVB mice which were harvested 14 days later | Atrophy |
DEXA | 8 weeks | FVB mice treated by a daily subcutaneous injection of 5 mg/kg DEXA for 4 days | Atrophy |
Pak1 KO | 8–9 weeks | C57Bl/6 mice presenting a whole-body 2 kb deletion of the genomic Pak1 DNA | None |